Drug factory · FDA FEI 3006341547

Cytovance Biologics, Inc.

800 Research Parkway, Oklahoma City, OK, United States

United States: 1

Problems found, fixed voluntarily at FDA's last inspection, Jun 17, 2026.

Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.

3 drug inspections on record since 2017: 1 with no problems, 2 with problems fixed voluntarily, 0 with FDA action.

What it does, for whom

DrugRoleForNDC
TagraxofuspMakes the active ingredient and tests it Stemline Therapeutics, Inc. 72187-0401

FDA inspection history

EndedResultProgramProblems noted
Jun 17, 2026Problems found, fixed voluntarilyDrug Quality Assurance—
May 9, 2019No problems foundDrug Quality Assurance—
Jul 20, 2017Problems found, fixed voluntarilyDrug Quality Assurance—

Registered with FDA for: analysis; api manufacture.